Filtered By:
Condition: Hypertension
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 587 results found since Jan 2013.
Loss of lung microvascular endothelial Piezo2 expression impairs NO synthesis, induces EndMT and is associated with pulmonary hypertension
Am J Physiol Heart Circ Physiol. 2022 Sep 23. doi: 10.1152/ajpheart.00220.2022. Online ahead of print.ABSTRACTMechanical forces are translated into biochemical stimuli by mechanotransduction channels, such as the mechanically-activated cation channel Piezo2. Lung Piezo2 expression has recently been shown to be restricted to endothelial cells. Hence, we aimed to investigate the role of Piezo2 in regulation of pulmonary vascular function and structure as well as its contribution to development of pulmonary arterial hypertension (PAH). The expression of Piezo2 was significantly reduced in pulmonary microvascular endothelial c...
Source: American Journal of Physiology. Heart and Circulatory Physiology - September 23, 2022 Category: Physiology Authors: Siyu Tian Zongye Cai Payel Sen Denise van Uden Esther van de Kamp Raphael Thuillet Ly Tu Christophe Guignabert Karin Boomars Kim Van der Heiden Maarten M Brandt Daphne Merkus Source Type: research
Inhibition of MyD88 attenuates angiotensin II-induced hypertensive kidney disease via regulating renal inflammation
CONCLUSION: These results demonstrate that Ang II induces inflammation and fibrosis in renal tubular epithelial cells through MyD88 and present MyD88 as a potential point of intervention for hypertension-associated kidney disease.PMID:36116148 | DOI:10.1016/j.intimp.2022.109218
Source: International Immunopharmacology - September 18, 2022 Category: Allergy & Immunology Authors: Ke Lin Wu Luo Na Yang Lan Su Hao Zhou Xiang Hu Yi Wang Zia A Khan Weijian Huang Gaojun Wu Guang Liang Source Type: research
DNA-PKcs participated in hypoxic pulmonary hypertension
CONCLUSIONS: Our study indicated the potential mechanism of DNA-PKcs in the development of HPH. It might provide insights into new therapeutic targets for pulmonary vascular remodeling and pulmonary hypertension.PMID:36114572 | DOI:10.1186/s12931-022-02171-x
Source: Cell Research - September 16, 2022 Category: Cytology Authors: Ying-Ying Liu Wei-Yun Zhang Meng-Lan Zhang Yu-Ji Wang Xi-Yan Ma Jung-Hong Jiang Ran Wang Da-Xiong Zeng Source Type: research
Melatonin activates the Mst1-Nrf2 signaling to alleviate cardiac hypertrophy in pulmonary arterial hypertension
This study aims to suggest one such possible treatment, through investigating the cardio-protective capabilities of the anti-oxidant, melatonin (Mel), for treating adverse RV remodeling in PAH, along with its underlying mechanisms. Arginine vasopressin induced neonatal rat cardiomyocyte hypertrophy in vitro; in vivo, PAH was induced in rats through intraperitoneal monocrotaline (MCT) injections, and Mel was administered intraperitoneally 24 h prior to MCT. Mel reduced rat cardiomyocyte hypertrophy and mitochondrial oxidative stress in vitro by activating the Mst1-Nrf2 pathway, which were all reversed upon siRNA knockdown o...
Source: European Journal of Pharmacology - September 13, 2022 Category: Drugs & Pharmacology Authors: Shuang Chen Ping Sun You Li Wenqian Shen Chao Wang Peng Zhao Hao Cui Jing-Yi Xue Guo-Qing Du Source Type: research
